Wall Street Zen Upgrades Gossamer Bio (NASDAQ:GOSS) to Hold

Gossamer Bio (NASDAQ:GOSS) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Several other brokerages have also recently issued reports on GOSS. Weiss Ratings raised Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. Leerink Partners raised Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price target for the company in a research report on Tuesday, July 28th. Finally, HC Wainwright restated a “buy” rating on shares of Gossamer Bio in a research note on Thursday, August 27th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $256.00.

Gossamer Bio Price Performance

Shares of NASDAQ GOSS opened at $10.73 on Friday. Gossamer Bio has a 1-year low of $9.10 and a 1-year high of $309.60. The business’s 50 day moving average is $13.44 and its two-hundred day moving average is $21.15. The stock has a market capitalization of $31.44 million, a P/E ratio of -0.19 and a beta of 2.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of GOSS. Corient Private Wealth LP lifted its stake in shares of Gossamer Bio by 41.3% in the second quarter. Corient Private Wealth LP now owns 5,632,698 shares of the company’s stock worth $927,000 after buying an additional 1,647,315 shares in the last quarter. Hsbc Holdings PLC grew its stake in Gossamer Bio by 1,289.4% during the 2nd quarter. Hsbc Holdings PLC now owns 1,583,118 shares of the company’s stock valued at $267,000 after acquiring an additional 1,469,175 shares in the last quarter. Bank of America Corp DE purchased a new stake in Gossamer Bio during the 2nd quarter valued at about $65,000. Hhlr Advisors LTD. acquired a new stake in Gossamer Bio in the 2nd quarter valued at about $819,000. Finally, ARCH Venture Management LLC acquired a new stake in Gossamer Bio in the 2nd quarter valued at about $1,326,004. 81.23% of the stock is owned by hedge funds and other institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.